Guardant Health (GH) Stock Forecast & Price Target

$162.78 +1.80 (+1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$162.10 -0.68 (-0.42%)

As of 04:28 PM Eastern

Compare

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
0

Buy
25

Based on 26 Wall Street analysts who have issued ratings for Guardant Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 24 have given a buy rating, and 1 has given a strong buy rating for GH.

Consensus Price Target

$187.71
15.31% Upside

According to the 26 analysts' twelve-month price targets for Guardant Health, the average price target is $187.71. The highest price target for GH is $225.00, while the lowest price target for GH is $120.00. The average price target represents a forecasted upside of 15.31% from the current price of $162.78.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Guardant Health and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GH Analyst Ratings Over Time

Type	Current Forecast 9/9/25 to 9/9/26	1 Month Ago 8/10/25 to 8/10/26	3 Months Ago 6/11/25 to 6/11/26	1 Year Ago 9/9/24 to 9/9/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	24 Buy rating(s)	23 Buy rating(s)	21 Buy rating(s)	17 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$187.71	$183.78	$141.95	$58.24
Forecasted Upside	15.31% Upside	9.91% Upside	8.44% Upside	-2.03% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

GH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Guardant Health Stock vs. The Competition

Type	Guardant Health	Healthcare Companies	Broader Market
Consensus Rating Score	2.96	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	14.51% Upside	912.10% Upside	16.38% Upside
News Sentiment Rating	Neutral News See Recent GH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/9/2026	UBS Group 4 of 5 stars	Dan Leonard 3 of 5 stars	Boost Target	Buy	$175.00 ➝ $225.00	+35.60%
9/8/2026	Rothschild & Co Redburn 4 of 5 stars	Jamie Clark Not Rated	Initiated Coverage	Buy	$203.00	+25.77%
9/2/2026	BTIG Research 3 of 5 stars	Mark Massaro 1 of 5 stars	Reiterated Rating	Buy	$195.00	+18.61%
8/25/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Brennan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
8/4/2026	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mason Carrico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$170.00 ➝ $195.00	+22.77%
8/4/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$135.00 ➝ $193.00	+21.51%
8/4/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shannon O'Callaghan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$175.00 ➝ $185.00	+16.48%
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$185.00 ➝ $200.00	+23.69%
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$130.00 ➝ $180.00	+6.54%
7/31/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evie Koslosky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$210.00	+37.84%
Get the Latest News and Ratings for GH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.
7/31/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$175.00 ➝ $200.00	+31.28%
7/31/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$150.00 ➝ $200.00	+31.28%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$185.00 ➝ $195.00	+21.40%
7/17/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
7/16/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$160.00 ➝ $190.00	+16.59%
7/14/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Mikson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$135.00 ➝ $205.00	+29.42%
7/8/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$150.00 ➝ $215.00	+31.97%
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$200.00	+18.48%
7/6/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ryskin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$135.00 ➝ $190.00	+13.11%
7/2/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eve Burstein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$175.00 ➝ $200.00	+17.12%
6/2/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$150.00	+16.15%
2/23/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$129.00	+28.03%
2/20/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Puneet Souda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$170.00 ➝ $180.00	+74.59%
2/20/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Couillard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$120.00 ➝ $125.00	+20.02%
2/17/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Catherine Ramsey Schulte Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$120.00	+14.45%
9/25/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
7/31/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sung Ji Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$57.00 ➝ $60.00	+37.49%
5/1/2025	TD Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Brennan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$56.00 ➝ $60.00	+24.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:29 PM ET.

GH Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Guardant Health is $187.71, with a high forecast of $225.00 and a low forecast of $120.00.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There is currently 1 sell rating, 24 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares.

According to analysts, Guardant Health's stock has a predicted upside of 15.31% based on their 12-month stock forecasts.

Over the previous 90 days, Guardant Health's stock had 1 upgrade by analysts.

Guardant Health has been rated by research analysts at Bank of America, Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Evercore, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, Stephens, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Guardant Health more than other "healthcare" companies. The consensus rating for Guardant Health is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how GH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Guardant Health Recommendations

MarketBeat monitors more than a dozen sources for Guardant Health analyst ratings, with the most recent rating issued on 9/9/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Guardant Health (GH) Stock Forecast & Price Target

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GH Analyst Ratings Over Time

GH Analyst Recommendations By Month

GH Price Targets by Month

Guardant Health Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

GH Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Guardant Health Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Guardant Health (GH) Stock Forecast & Price Target

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GH Analyst Ratings Over Time

GH Analyst Recommendations By Month

GH Price Targets by Month

Guardant Health Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

GH Forecast - Frequently Asked Questions

What is Guardant Health's forecast for 2026?

Should I buy or sell Guardant Health stock right now?

Does Guardant Health's stock price have much upside?

Has Guardant Health been upgraded by Wall Street analysts recently?

What analysts cover Guardant Health?

Do Wall Street analysts like Guardant Health more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Guardant Health Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools